SBIR/STTR Research Award
Diametrically Patterned Dural Graft for Enhanced Dura Mater Regeneration
Award amount
$1,351,152Program and phase
SBIR · Phase IIAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NANONERVE, INC.
- Proposal award date
- 2013-09-16
- Contract end date
- 2016-08-31
- UEI
- Not reported
- Solicitation number
- PA12-088
- Topic code
- NINDS
Research abstract
DESCRIPTION provided by applicant NanoNerve is developing a novel diametrically patterned nanofibrous dural substitute for rapid dura mater regeneration following neurosurgical procedures In the US alone neurosurgical procedures are performed annually that require patching of the dura mater to prevent leakage infection and neural damage Currently available dural substitutes include xenogenic collagen matrices and permanent synthetic devices Xenogeneic collagen matrices have significant disadvantages including low mechanical strength low suturability and high cost and disease transmission risks The permanent synthetic devices also suffer from major disadvantages including resistance to dura mater regeneration need for extensive suturing during implantation and higher leakage rates The overall goal of the project is FDA K clearance and commercialization of a highly versatile diametrically patterned nanofibrous dural substitute NanoNerve is utilizing its patent pending electrospinning technology to diametrically pattern nanofibers for rapidly regenerating dural tissue from the entire periphery of the defect toward the center NanoNerveandapos s synthetic bioresorbable nanofibrous dural substituteandapos s ultra thin profile and high mechanical strength will enable it to become the first synthetic dural substitute capable of sutured and suture free implantation This Phase II project will continue development of the diametrically patterned nanofibrous dural substitute by performing biocompatibility safety stability and long term in viv implantation studies Upon achievement of Phase II milestones NanoNerve will file an FDA IDE application for human clinical testing and eventually an FDA k for market clearance PUBLIC HEALTH RELEVANCE Over neurosurgical procedures are performed annually that require grafting of the dura mater to prevent fluid leakage infection and neural tissue damage Currently available dural substitutes have major limitations including incomplete dural repair low mechanical strength and high leakage rate complications This phase II study will enable development of a strong versatile and diametrically patterned nanofibrous dural substitute for rapid and effective dura mater regeneration
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Enhancing Healthcare Delivery and Patient Outcomes: Noninvasive Wireless Sensors to Improve Ventricular Shunt Monitoring, Reduce Imaging, and Alleviate the Burden on Providers, Patients, and Families
- Commercialization Readiness Pilot for Flow Acceleration for Stroke Thrombolysis (FAST) System
- 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development
- Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries
- Promoting tissue repair and functional recovery after spinal cord injury by targeting the microtubule regulatory protein Fidgetin-like 2: Supplement for Imaging System